ethyl 3-phenylisonicotinate | 1261743-67-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 3-phenylisonicotinate
• 英文别名: Ethyl 3-phenylpyridine-4-carboxylate；ethyl 3-phenylpyridine-4-carboxylate
• CAS: 1261743-67-2
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: UGBUMAOJLQHBLB-UHFFFAOYSA-N

物化性质

• 沸点：
  375.1±30.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-phenylisonicotinate 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 potassium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 1.0h， 生成 2-(2,3-dihydro-1-benzofuran-5-yl)ethyl 1-methyl-5-phenyl-3,6-dihydro-2H-pyridine-4-carboxylate
  参考文献：
  名称：

  Structural Modifications to Tetrahydropyridine-3-carboxylate Esters en Route to the Discovery of M₅-Preferring Muscarinic Receptor Orthosteric Antagonists

  摘要：

  The M-5 muscarinic acetylcholine receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abuse. We describe herein the discovery of a series of M-5-preferring orthosteric antagonists based on the scaffold of 1,2,5,6-tetrahydropyridine-3-carboxylic acid. Compound 56, the most selective compound in this series, possesses an 11-fold selectivity for the M-5 over M-1 receptor and shows little activity at M-2-M-4. This compound, although exhibiting modest affinity (K-i = 2.24 mu M) for the [H-3]N-methylscopolamine binding site on the M-5 receptor, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [H-3]DA release from rat striatal slices. Further, a homology model of human M-5 receptor based on the crystal structure of the rat M-3 receptor was constructed, and docking studies of compounds 28 and 56 were performed in an attempt to understand the possible binding mode of these novel analogues to the receptor.

  DOI：

  10.1021/jm301774u
• 作为产物：
  描述：

  3-溴异烟酸 在 四(三苯基膦)钯 、 硫酸 、 sodium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 ethyl 3-phenylisonicotinate
  参考文献：
  名称：

  Structural Modifications to Tetrahydropyridine-3-carboxylate Esters en Route to the Discovery of M₅-Preferring Muscarinic Receptor Orthosteric Antagonists

  摘要：

  The M-5 muscarinic acetylcholine receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abuse. We describe herein the discovery of a series of M-5-preferring orthosteric antagonists based on the scaffold of 1,2,5,6-tetrahydropyridine-3-carboxylic acid. Compound 56, the most selective compound in this series, possesses an 11-fold selectivity for the M-5 over M-1 receptor and shows little activity at M-2-M-4. This compound, although exhibiting modest affinity (K-i = 2.24 mu M) for the [H-3]N-methylscopolamine binding site on the M-5 receptor, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [H-3]DA release from rat striatal slices. Further, a homology model of human M-5 receptor based on the crystal structure of the rat M-3 receptor was constructed, and docking studies of compounds 28 and 56 were performed in an attempt to understand the possible binding mode of these novel analogues to the receptor.

  DOI：

  10.1021/jm301774u

文献信息

• INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
  申请人：Praxis Biotech LLC

  公开号：US20190185451A1

  公开（公告）日：2019-06-20

  Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

  描述了用于调节成纤维细胞活化蛋白（FAP）的化合物和组合物。这些化合物和组合物可能被用作治疗疾病的治疗剂，包括高增殖性疾病。
• Direct Arylation of Substituted Pyridines with Arylboronic Acids Catalyzed by Iron(II) Oxalate
  作者：Yibo Huang、Dan Guan、Liang Wang

  DOI：10.1002/cjoc.201400528

  日期：2014.12

  The direct arylation of substituted pyridines with several arylboronic acids has been developed. This transformation could proceed readily at ambient temperature using inexpensive reagents: iron(II) oxalate as a catalyst, potassium persulfate as a co‐oxidant, which can afford the arylated products in mild to good yields. The mechanism is presumed to proceed through a nucleophilic radical addition to

  已经开发了取代的吡啶与几种芳基硼酸的直接芳基化。使用廉价的试剂：草酸亚铁（II）作为催化剂，过硫酸钾作为助氧化剂，可以在环境温度下轻松进行这种转化，从而可以提供中等收率到良好收率的芳基化产物。推测该机理是通过原位再氧化将亲核基团加到吡啶上进行的。
• 吡啶衍生物的直接芳香化工艺
  申请人：常州工程职业技术学院

  公开号：CN103755631B

  公开（公告）日：2016-03-02

  本发明涉及芳香类吡啶衍生物的制备工艺技术领域，具体涉及一种吡啶衍生物的直接芳香化工艺，该工艺流程如下：在烧瓶中依次加入吡啶衍生物、芳硼酸、亚铁盐、三氟乙酸物料，将上述混合物在室温下搅拌均匀，加入过二硫酸盐继续搅拌，反应结束后，将所得产物过滤、萃取、浓缩、分离，即得到吡啶的芳香化衍生物。本发明采用亚铁盐作为催化剂，过二硫酸盐作为氧化剂，利用过二硫酸根氧化亚铁离子反应过程中促使芳硼酸产生芳基自由基，芳基自由基加成到吡啶衍生物中，从而获得相应产物，生产成本较低、反应收率较高，适宜推广使用。
• [EN] INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN<br/>[FR] INHIBITEURS DE LA PROTÉINE D'ACTIVATION DES FIBROBLASTES
  申请人：PRAXIS BIOTECH LLC

  公开号：WO2019118932A1

  公开（公告）日：2019-06-20

  Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
• Structural Modifications to Tetrahydropyridine-3-carboxylate Esters en Route to the Discovery of M₅-Preferring Muscarinic Receptor Orthosteric Antagonists
  作者：Guangrong Zheng、Andrew M. Smith、Xiaoqin Huang、Karunai L. Subramanian、Kiran B. Siripurapu、Agripina Deaciuc、Chang-Guo Zhan、Linda P. Dwoskin

  DOI：10.1021/jm301774u

  日期：2013.2.28

  The M-5 muscarinic acetylcholine receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abuse. We describe herein the discovery of a series of M-5-preferring orthosteric antagonists based on the scaffold of 1,2,5,6-tetrahydropyridine-3-carboxylic acid. Compound 56, the most selective compound in this series, possesses an 11-fold selectivity for the M-5 over M-1 receptor and shows little activity at M-2-M-4. This compound, although exhibiting modest affinity (K-i = 2.24 mu M) for the [H-3]N-methylscopolamine binding site on the M-5 receptor, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [H-3]DA release from rat striatal slices. Further, a homology model of human M-5 receptor based on the crystal structure of the rat M-3 receptor was constructed, and docking studies of compounds 28 and 56 were performed in an attempt to understand the possible binding mode of these novel analogues to the receptor.